Grants

• 2016 - European Fund for Strategic Investments (EFSI-EIF)

This EU-guaranteed loan, provided by ING Luxembourg and backed by EIF under the Investment Plan for Europe, aimed to generate new investments by facilitating access to finance for small- and medium-sized enterprises. The loan was used to further establish our research and development activities.

• 2017-2020 - MECO-RDI (LU): Flexible Engineering Applying Capsule Technologies and In Vitro Artificial Tissue Models to Explore Solutions for Hyperpigmentation and Biofilm-Related Disorders

This project focused on developing technologies to treat hyperpigmentation disorders and create models for investigating these technologies. By applying encapsulation technologies, the goal was to overcome the limitations of ingredients in existing marketed products, particularly regarding toxicity, efficacy, and stability. In response to new EU regulations restricting animal testing, the project aimed to develop in vitro skin models for pigmentation disorders and biofilm-infected wounds, addressing the limitations of current skin models. These skin-equivalent models were used to assess the encapsulation technologies.

• 2021 - Radiation Nuclear Countermeasures Program, DAIT, NIAID, NIH (US): Testing Mitigative Effects of Flamigel on Skin Wound Healing from Radiation Combined Injury in Experimental Mice

In a real nuclear detonation scenario, radiation combined injury (RCI, radiation exposure coupled with other forms of injury, such as burn, wound, blast, hemorrhage, and/or sepsis) are estimated to comprise up to 65% of all injuries observed, significantly increasing the risk of morbidity and mortality compared to that of radiation alone. This project aimed to use a newly developed mouse model of wound trauma combined with radiation combined injury (RCI) to evaluate the wound-healing properties of Flamigel under these conditions.

• 2021–2024 - MECO-RDI (LU) - Integrative Technology Platforms to Revolutionize Wound-Care Treatment Developments

The aim of this project was to conduct fundamental research on novel wound driver pathways and establish a knowledge base for industrial research on an innovative technology platform. This platform was intended to help overcome current challenges in the development of strategies for treating non-healing chronic wounds. The research initially focused on identifying driver genes associated with wound healing processes. This theoretical approach included investigating microbial resistance drivers (which aggravate or impair wound healing), as well as factors related to cell migration and wound progression. In the second part, integrative treatments for non-healing chronic wounds, based on the initial research findings, were evaluated.

• 2023-2025 - Flanders Innovation & Entrepreneurship (VLAIO): Research on Recombinant Engineering of Wound-Healing Enzymes

Flen Health has been awarded a grant by Flanders Innovation & Entrepreneurship (VLAIO) to further leverage its leading expertise in biological wound treatment research and development. The project aims to research and develop pharmaceutical wound healing enzymes via recombinant engineering to accelerate the deployment of our unique enzyme technology for topical wound treatment of non-healing and chronic wounds.